How did lurbinectedin's side effects alter dosage scheduling?

Lurbinectedin’s main dose‑limiting toxicities are hematologic (neutropenia, thrombocytopenia) and hepatotoxicity. Because of these, the dosing schedule is often adjusted rather than kept strictly on a fixed 21‑day cycle.

How toxicity changes scheduling in practice:
- Hematologic toxicity (neutropenia/thrombocytopenia):
- If a cycle is associated with grade 3–4 neutropenia or platelets, the cycle is delayed until counts recover to acceptable levels (e.g., ANC and platelets return to a safe range).
- When a cycle is re‑started after recovery, the next dose is typically reduced (commonly about 25% reduction from the prior dose). If toxicity recurs, further reductions or longer delays may be used.
- Hepatic toxicity (elevated liver enzymes, bilirubin):
- If liver function worsens, treatment is held and then resumed at a reduced dose or with a longer delay until hepatic indices recover.
- Non‑hematologic toxicity (e.g., nausea, mucositis, fatigue):
- Moderate to severe non‑hematologic toxicities can also lead to delays and/or dose reductions for subsequent cycles.

In short, side effects mainly drive delays in starting subsequent cycles and reductions in dose (often starting at ~25% lower) rather than keeping the exact same schedule. The 21‑day cycle is generally preserved, but actual timing and dose depend on how quickly counts and liver function recover. Always follow the specific labeling and your clinician’s guidance for thresholds and exact dose modification steps.